SCHEMBL70978

SCHEMBL70978

CC(=O)c1cccnc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.61
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
MAPT P10636 2/20 0.45
CYP3A4 P08684 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
BLM P54132 1/20 0.45
AGER Q15109 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
MYC P01106 1/20 0.44
NAPRT Q6XQN6 2/20 0.44
LMNA P02545 1/20 0.44
MKNK1 Q9BUB5 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29496114 1.00 P2RX7 (0.61) P2RX7KDM4EALDH1A1TDP1L3MBTL1
SCHEMBL11078263 0.84 P2RX7 (0.63) P2RX7KDM4EALDH1A1TDP1L3MBTL1
SCHEMBL12230958 0.83 P2RX7 (0.61) P2RX7KDM4EALDH1A1TDP1L3MBTL1
SCHEMBL29651292 0.83 KDM4E (0.63) P2RX7KDM4EALDH1A1TDP1L3MBTL1
SCHEMBL71547 0.83 KDM4E (0.63) P2RX7KDM4EALDH1A1TDP1L3MBTL1
SCHEMBL2785276 0.81 P2RX7 (0.44) P2RX7KDM4EALDH1A1TDP1MAPT
SCHEMBL7642752 0.81 P2RX7 (0.59) P2RX7KDM4EALDH1A1TDP1L3MBTL1
Iodide SCHEMBL10567955 0.81 KDM4E (0.61) P2RX7KDM4EALDH1A1TDP1L3MBTL1
SCHEMBL724087 0.81 P2RX7 (0.65) P2RX7KDM4EALDH1A1TDP1L3MBTL1
SCHEMBL7715770 0.81 KDM4E (0.61) P2RX7KDM4EALDH1A1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024046712-A1 METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE Forschungszentrum Jülich GmbH (DE) 2024-03-07 WO claimed
CN-101494999-A Method for using organic compound GIVAUDAN SA (CH) 2009-07-29 CN claimed
WO-2008062324-A2 COMPOSITIONS COMPRISING NICOTINAMIDE AND WAKAME EXTRACT HAVING SKIN ANTI-AGING PROPERTIES DERMENA (CA) 2008-05-29 WO claimed
US-6358631-B1 LIGHT EMITTING DEVICE STRUCTURE WITH STACKS AND LAYERS OF TRANSPARENT CONDUCTIVE LAYERS THE TRUSTEES OF PRINCETON UNIVERSITY 2002-03-19 US claimed
EP-0947122-A4 MIXED VAPOR DEPOSITED FILMS FOR ELECTROLUMINESCENT DEVICES UNIV PRINCETON (US) 2001-10-08 EP claimed
US-20010014391-A1 Multicolor; vertical stack FORREST STEPHEN ROSS (US) 2001-08-16 US claimed
EP-0947122-A1 MIXED VAPOR DEPOSITED FILMS FOR ELECTROLUMINESCENT DEVICES The Trustees of Princeton University (US) 1999-10-06 EP claimed
EP-0808244-A4 MULTICOLOR ORGANIC LIGHT EMITTING DEVICES UNIV PRINCETON (US) 1998-04-29 EP claimed
WO-1998006242-A1 MIXED VAPOR DEPOSITED FILMS FOR ELECTROLUMINESCENT DEVICES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1998-02-12 WO claimed
US-5707745-A DISPLAYS FOR ELECTRONICS IN STACKS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1998-01-13 US claimed
EP-0808244-A2 MULTICOLOR ORGANIC LIGHT EMITTING DEVICES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1997-11-26 EP claimed
WO-1996019792-A2 MULTICOLOR ORGANIC LIGHT EMITTING DEVICES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1996-06-27 WO claimed
US-20250382290-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-12-18 US disclosed
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
EP-4543450-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-30 EP disclosed
US-4338446-A Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates STERLING DRUG INC. (US) 1982-07-06 US disclosed
US-4305943-A 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics STERLING DRUG INC. (US) 1981-12-15 US disclosed
US-4304776-A 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics STERLING DRUG INC. (US) 1981-12-08 US disclosed
US-3969363-A CARDIOVASCULAR DISORDERS CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1976-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382290-A1 SALTS OF SOS1 INHIBITORS SOS1, SOS2, SOST P2RX7 3454/4885KDM4E 3149/4885ALDH1A1 3158/4885
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 P2RX7 4209/4885KDM4E 3245/4885ALDH1A1 3260/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 P2RX7 4209/4885KDM4E 3245/4885ALDH1A1 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.